1Ronde G, Rob V B, Filip S, et al. Risk factors for 12-month com-orbidity of mood, anxiety, and substance use disorders: findings from the netherlands mental health survey and incidence study[J]. Am J Psychiatry, 2002,159(6):620-629.
2Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study[J]. Br J Psychiatry, 2001,179(1):15-22.
3Sartorius N, Ustan T B, Lecrubier Y, et al. Derpression comorbid with anxiety:results from the WHO study on psychological disorders in primary health care[J]. Br J Psychiatry, 1996,168(1):38-45.
4Stephen M S. Essential psychopharmacology: neuroscientific basis and practical applications[M]. London: Cambridge University Press, 2001.250-259.
5Doraiswamy P M. Contemporary management of comorbid anxiety and depression in geriatric patients[J]. J Clin Psycgiatry, 2001,62(Suppl 12):30-35.
6Thase M E, Entsuag A R, Rudolph R L. Remission rates during treatment with venlafaxine or selective serltlnin reuptakeinhibitors[J]. Br J Psychiatry, 2001,178(3):234-241.
7Angst J. Depression and anxiety:implications for nosology, course, and treatment[J]. J Clin Psychiatry, 1997,58(Suppl 8):3-5.
8Nutt D J.Care of depressed patients with anxiety symptoms[J]. J Clin Psychiatry, 1999,60(Suppl 17):23-27.
9Stein D J. Comorbidity in generalized anxiety disorder: impact and impli-cations[J]. J Clin Psychiatey, 2001,62(Suppl 11):29-34.
